The International Journal of Neuropsychopharmacology

As this article doesn't contain an abstract, the image below is necessary to enable the article to be indexed by certain search engines. The resolution of the full-text PDF is much higher than that shown here.

Focus

Bridging pharmacology and neurodevelopment in schizophrenia

Tadafumi Katoa1 c1

a1 Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute

(Received March 13 2007)

(Reviewed June 06 2007)

(Revised June 06 2007)

(Accepted June 06 2007)

(Online publication July 26 2007)

Correspondence:

c1 Address for correspondence: Dr T. Kato, Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Hirosawa 2-1 Wako 351-0198, Japan. Tel.: +81-48-467-6949 Fax: +81-48-467-6947 Email: kato@brain.riken.jp

Footnotes

See Ito et al. (this issue). Effects of schizophrenomimetics on the expression of the CCN1 (CYR 61) gene encoding a matricellular protein in the infant and adult neocortex of the mouse and rat.

Related Content